Moreover, the beneficial effects of angiotensin-converting enzyme inhibitors (ACEI) and spironolactone in patients with congestive heart failure (CHF) have been showed in both species, indirectly proving the negative impact of chronic RAAS stimulation [1, 19–22]. The gene discussed is ACE; the disease is congestive heart failure.